FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137511650> ?p ?o ?g. }

• W2137511650 abstract "This study compared the efficacy and tolerability of the cyclooxygenase-2-selective inhibitor valdecoxib with the nonselective NSAID naproxen and with placebo in treating severe rheumatoid arthritis (RA).This 12-week, multicenter, randomized, double-blind, placebo-controlled study compared the efficacy and tolerability of valdecoxib 10 mg QD (n = 170) or naproxen 500 mg BID (n = 167) with placebo (n = 171) in treating the signs and symptoms of severe RA. Study patients were aged >or=18 years and were diagnosed as having RA for >or=6 months that was stable due to a treatment regimen. Severe RA was defined as a physician's and patient's global assessment of disease activity of fair, poor, or very poor at baseline; >or=6 tender or painful joints; >or=3 swollen joints; >or=45 minutes of morning stiffness; a visual analog scale pain rating of >or=40 mm; or increases since baseline in these measures. Efficacy outcome measures included the percentage of patients achieving an American College of Rheumatology Responder Index 20% (ACR-20) at weeks 1, 6 and 12. Adverse events (AEs) were graded by the investigator as mild, moderate, or severe at weeks 1, 6, and 12.Of the 508 patients randomized, 340 completed the study. The study groups were comparable for age, ethnic origin, weight, height, and concomitant medications, but the naproxen group had significantly more men (29% [49/167]) than the valdecoxib (18% [31/170]) and placebo (16% [27/171]) groups. The percentage of patients achieving an ACR-20 response was significantly greater in the valdecoxib and naproxen treatment groups (58.8% [100/170] and 60.8% [101/166], respectively) than in the placebo group (39.6% [67/169]) at week 12 (both, P < 0.001). The percentage of patients achieving an ACR-20 response was significantly greater in the naproxen group than in the placebo group at both week 1 (53.6% [89/166] vs 37.9% [64/169]; P = 0.003) and week 6 (64.5% [107/166] vs 46.7% [79/169]; P = 0.001), and in the valdecoxib group compared with placebo at week 1 (52.9% [90/170]; P = 0.008) but not at week 6. Patients in the valdecoxib and naproxen groups had significantly improved efficacy compared with placebo in most of the other secondary assessments of inflammation, pain, and function. The incidence of AEs was similar in all groups (valdecoxib, 54.1% [92/170]; naproxen, 55.4% [92/166]; and placebo, 52.9% [90/170]).Valdecoxib 10 mg QD administered over 12 weeks was significantly better than placebo and similar to naproxen 500 mg BID in treating the signs and symptoms of severe RA in these patients." @default.
• W2137511650 created "2016-06-24" @default.
• W2137511650 creator A5011125671 @default.
• W2137511650 creator A5014688560 @default.
• W2137511650 creator A5017793255 @default.
• W2137511650 creator A5029626831 @default.
• W2137511650 creator A5059093901 @default.
• W2137511650 date "2007-06-01" @default.
• W2137511650 modified "2023-09-26" @default.
• W2137511650 title "Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: A 12-week, multicenter, randomized, double-blind, placebo-controlled study" @default.
• W2137511650 cites W104470354 @default.
• W2137511650 cites W1483647539 @default.
• W2137511650 cites W166415211 @default.
• W2137511650 cites W1978103379 @default.
• W2137511650 cites W1984407986 @default.
• W2137511650 cites W1985004174 @default.
• W2137511650 cites W1990371285 @default.
• W2137511650 cites W1994542115 @default.
• W2137511650 cites W2001683083 @default.
• W2137511650 cites W2014751942 @default.
• W2137511650 cites W2015173447 @default.
• W2137511650 cites W2017082074 @default.
• W2137511650 cites W2020317622 @default.
• W2137511650 cites W2032140498 @default.
• W2137511650 cites W2033299724 @default.
• W2137511650 cites W2047442015 @default.
• W2137511650 cites W2060125667 @default.
• W2137511650 cites W2067364570 @default.
• W2137511650 cites W2067506928 @default.
• W2137511650 cites W2083673654 @default.
• W2137511650 cites W2088158803 @default.
• W2137511650 cites W2090007958 @default.
• W2137511650 cites W2095493602 @default.
• W2137511650 cites W2098318549 @default.
• W2137511650 cites W2098487604 @default.
• W2137511650 cites W2098767548 @default.
• W2137511650 cites W2102307364 @default.
• W2137511650 cites W2103709037 @default.
• W2137511650 cites W2108840350 @default.
• W2137511650 cites W2118840514 @default.
• W2137511650 cites W2119339197 @default.
• W2137511650 cites W2124678826 @default.
• W2137511650 cites W2133604058 @default.
• W2137511650 cites W2135983738 @default.
• W2137511650 cites W2149377741 @default.
• W2137511650 cites W2150752342 @default.
• W2137511650 cites W2152348310 @default.
• W2137511650 cites W2152388556 @default.
• W2137511650 cites W2154787313 @default.
• W2137511650 cites W2159106700 @default.
• W2137511650 cites W2162716725 @default.
• W2137511650 cites W2167167020 @default.
• W2137511650 cites W2168711492 @default.
• W2137511650 cites W2294550615 @default.
• W2137511650 cites W2319957449 @default.
• W2137511650 cites W2326789779 @default.
• W2137511650 cites W2340084730 @default.
• W2137511650 cites W2340829617 @default.
• W2137511650 cites W2413007761 @default.
• W2137511650 cites W2414963325 @default.
• W2137511650 cites W2419453098 @default.
• W2137511650 cites W3146223861 @default.
• W2137511650 cites W3150912274 @default.
• W2137511650 cites W614531583 @default.
• W2137511650 cites W2132150662 @default.
• W2137511650 doi "https://doi.org/10.1016/j.clinthera.2007.06.016" @default.
• W2137511650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17692722" @default.
• W2137511650 hasPublicationYear "2007" @default.
• W2137511650 type Work @default.
• W2137511650 sameAs 2137511650 @default.
• W2137511650 citedByCount "9" @default.
• W2137511650 countsByYear W21375116502012 @default.
• W2137511650 countsByYear W21375116502013 @default.
• W2137511650 countsByYear W21375116502015 @default.
• W2137511650 countsByYear W21375116502017 @default.
• W2137511650 countsByYear W21375116502021 @default.
• W2137511650 crossrefType "journal-article" @default.
• W2137511650 hasAuthorship W2137511650A5011125671 @default.
• W2137511650 hasAuthorship W2137511650A5014688560 @default.
• W2137511650 hasAuthorship W2137511650A5017793255 @default.
• W2137511650 hasAuthorship W2137511650A5029626831 @default.
• W2137511650 hasAuthorship W2137511650A5059093901 @default.
• W2137511650 hasConcept C126322002 @default.
• W2137511650 hasConcept C14184104 @default.
• W2137511650 hasConcept C142724271 @default.
• W2137511650 hasConcept C181199279 @default.
• W2137511650 hasConcept C185592680 @default.
• W2137511650 hasConcept C197934379 @default.
• W2137511650 hasConcept C198451711 @default.
• W2137511650 hasConcept C204787440 @default.
• W2137511650 hasConcept C27081682 @default.
• W2137511650 hasConcept C2777575956 @default.
• W2137511650 hasConcept C2778115740 @default.
• W2137511650 hasConcept C2778375690 @default.
• W2137511650 hasConcept C2778582115 @default.
• W2137511650 hasConcept C2779384505 @default.
• W2137511650 hasConcept C2779528491 @default.
• W2137511650 hasConcept C2779689624 @default.
• W2137511650 hasConcept C42219234 @default.
• W2137511650 hasConcept C55493867 @default.

• next